Deerfield Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Deerfield Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$76.3M	Buy	1,332,836 +481,280	+57%	+$26.4M	0.8%	36
2026 Q1	$48.1M	Buy	+851,556	New	+$49.7M	0.57%	47
2024 Q4	–	Sell	-9,255	Closed	-$651K	–	153
2024 Q3	$651K	Sell	9,255 -577	-6%	-$48.2K	0.01%	241
2024 Q2	$809K	Buy	+9,832	New	+$819K	0.01%	178
2021 Q1	–	Sell	-163,000	Closed	-$14.3M	–	136
2020 Q4	$14.3M	Buy	+163,000	New	+$12.9M	0.28%	89
2016 Q4	–	Sell	-13,800	Closed	-$1.28M	–	103
2016 Q3	$1.28M	Buy	+13,800	New	+$1.3M	0.06%	88
2013 Q3	–	Sell	-247,000	Closed	-$13.8M	–	119
2013 Q2	$13.8M	Buy	+247,000	New	+$15.4M	0.65%	53

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Deerfield Management's BMRN Position: Q2 2026 in Review

Deerfield Management increased its BioMarin Pharmaceuticals (BMRN) stake by 57% in Q2 2026, buying an estimated $26.4M and bringing the position to 1,332,836 shares worth $76.3M. The position accounts for 0.8% of the portfolio, ranked #36.

Deerfield Management first reported a position in BMRN in Q2 2013 and has held it in 7 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Deerfield Management held 1,332,836 shares of BioMarin Pharmaceuticals worth $76.3M as of Q2 2026.
Deerfield Management bought 481,280 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $26.4M.
BioMarin Pharmaceuticals made up 0.8% of Deerfield Management's portfolio in Q2 2026, its #36 holding.
Deerfield Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 7 quarters since.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.